Millions of Americans are eagerly awaiting a powerful new drug from Eli Lilly called retatrutide, which promises to treat severe obesity more effectively than previous GLP-1 class drugs.
Yet drugmaker Eli Lilly and the U.S. Food and Drug Administration have granted access to one man, through the FDA’s so-called “compassionate use” program.
Here & Now‘s Robin Young speaks with STAT reporter Lizzy Lawrence about why this person might be receiving special treatment.
This article was originally published on WBUR.org.
Copyright 2026 WBUR
